Joel Beatty
Stock Analyst at Baird
(4.32)
# 423
Out of 4,711 analysts
181
Total ratings
44.14%
Success rate
20.46%
Average return
Main Sectors:
Stocks Rated by Joel Beatty
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EDIT Editas Medicine | Maintains: Outperform | $10 → $8 | $1.31 | +510.69% | 3 | Dec 13, 2024 | |
| PTCT PTC Therapeutics | Maintains: Outperform | $52 → $70 | $46.24 | +51.38% | 14 | Dec 3, 2024 | |
| DRUG Bright Minds Biosciences | Initiates: Outperform | $75 | $38.65 | +94.05% | 1 | Nov 25, 2024 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Outperform | $154 → $162 | $122.97 | +31.74% | 3 | Nov 18, 2024 | |
| AMLX Amylyx Pharmaceuticals | Upgrades: Outperform | $3 → $11 | $4.05 | +171.60% | 4 | Nov 18, 2024 | |
| IMMP Immutep | Maintains: Outperform | $6 → $7 | $2.03 | +244.83% | 5 | Nov 15, 2024 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $112 → $116 | $90.73 | +27.85% | 3 | Nov 13, 2024 | |
| NGNE Neurogene | Maintains: Outperform | $54 → $72 | $22.64 | +218.02% | 2 | Nov 12, 2024 | |
| ARGX argenx SE | Downgrades: Neutral | $515 → $650 | $623.82 | +4.20% | 5 | Nov 1, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Neutral | $72 → $65 | $65.66 | -1.01% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $32 | $13.50 | +137.04% | 1 | Oct 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $240 → $175 | $128.66 | +36.02% | 4 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $9 | $5.61 | +60.43% | 4 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $10 | $7.84 | +27.55% | 3 | Sep 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $4.01 | +299.00% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $112 → $127 | $90.14 | +40.89% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $58 | $23.80 | +143.70% | 1 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $37 → $38 | $29.71 | +27.90% | 2 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $72 | $44.22 | +62.82% | 4 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $27 | $7.16 | +277.09% | 1 | May 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $45 → $20 | $1.36 | +1,370.59% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $28 | $16.87 | +65.98% | 3 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $117 | $76.52 | +52.90% | 1 | May 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $4.5 | $3.49 | +28.94% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $83 → $103 | $83.45 | +23.43% | 2 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $19.83 | +26.07% | 3 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $9 | $2.91 | +209.28% | 2 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $28 | $13.08 | +114.07% | 2 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $4.40 | +263.64% | 1 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $2.99 | +134.11% | 1 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $1.25 | $1.59 | -21.38% | 2 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $44 | $13.21 | +233.08% | 3 | Apr 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $58 | $19.45 | +198.20% | 6 | Feb 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $24 | $25.61 | -6.29% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $18 | $15.48 | +16.28% | 3 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $6 | $4.26 | +40.85% | 2 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $46 → $31 | $6.90 | +349.28% | 3 | Jun 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $36 → $28 | $7.34 | +281.47% | 2 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $170 → $175 | $245.44 | -28.70% | 2 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 | $4.78 | +192.89% | 8 | Jan 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $108 | $118.97 | -9.22% | 10 | Jan 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $78 | $35.63 | +118.92% | 3 | Aug 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $3.19 | +3,034.80% | 2 | Apr 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $6 | $0.46 | +1,204.35% | 14 | Apr 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $15 | $0.61 | +2,353.79% | 2 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $2.19 | - | 12 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $15 | $8.70 | +72.41% | 11 | Sep 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $120 | $1.03 | +11,550.49% | 2 | Aug 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $19 | $9.01 | +110.88% | 3 | Nov 10, 2017 |
Editas Medicine
Dec 13, 2024
Maintains: Outperform
Price Target: $10 → $8
Current: $1.31
Upside: +510.69%
PTC Therapeutics
Dec 3, 2024
Maintains: Outperform
Price Target: $52 → $70
Current: $46.24
Upside: +51.38%
Bright Minds Biosciences
Nov 25, 2024
Initiates: Outperform
Price Target: $75
Current: $38.65
Upside: +94.05%
Jazz Pharmaceuticals
Nov 18, 2024
Maintains: Outperform
Price Target: $154 → $162
Current: $122.97
Upside: +31.74%
Amylyx Pharmaceuticals
Nov 18, 2024
Upgrades: Outperform
Price Target: $3 → $11
Current: $4.05
Upside: +171.60%
Immutep
Nov 15, 2024
Maintains: Outperform
Price Target: $6 → $7
Current: $2.03
Upside: +244.83%
Axsome Therapeutics
Nov 13, 2024
Maintains: Outperform
Price Target: $112 → $116
Current: $90.73
Upside: +27.85%
Neurogene
Nov 12, 2024
Maintains: Outperform
Price Target: $54 → $72
Current: $22.64
Upside: +218.02%
argenx SE
Nov 1, 2024
Downgrades: Neutral
Price Target: $515 → $650
Current: $623.82
Upside: +4.20%
BioMarin Pharmaceutical
Oct 30, 2024
Maintains: Neutral
Price Target: $72 → $65
Current: $65.66
Upside: -1.01%
Oct 22, 2024
Initiates: Outperform
Price Target: $32
Current: $13.50
Upside: +137.04%
Oct 21, 2024
Maintains: Outperform
Price Target: $240 → $175
Current: $128.66
Upside: +36.02%
Oct 9, 2024
Maintains: Neutral
Price Target: $13 → $9
Current: $5.61
Upside: +60.43%
Sep 5, 2024
Maintains: Neutral
Price Target: $8 → $10
Current: $7.84
Upside: +27.55%
Sep 4, 2024
Initiates: Outperform
Price Target: $16
Current: $4.01
Upside: +299.00%
Aug 2, 2024
Maintains: Outperform
Price Target: $112 → $127
Current: $90.14
Upside: +40.89%
Jul 26, 2024
Initiates: Outperform
Price Target: $58
Current: $23.80
Upside: +143.70%
Jul 25, 2024
Maintains: Outperform
Price Target: $37 → $38
Current: $29.71
Upside: +27.90%
May 31, 2024
Maintains: Outperform
Price Target: $68 → $72
Current: $44.22
Upside: +62.82%
May 28, 2024
Initiates: Outperform
Price Target: $27
Current: $7.16
Upside: +277.09%
May 15, 2024
Maintains: Outperform
Price Target: $45 → $20
Current: $1.36
Upside: +1,370.59%
May 9, 2024
Maintains: Outperform
Price Target: $31 → $28
Current: $16.87
Upside: +65.98%
May 1, 2024
Initiates: Outperform
Price Target: $117
Current: $76.52
Upside: +52.90%
Apr 30, 2024
Downgrades: Neutral
Price Target: $4.5
Current: $3.49
Upside: +28.94%
Apr 17, 2024
Maintains: Outperform
Price Target: $83 → $103
Current: $83.45
Upside: +23.43%
Apr 11, 2024
Maintains: Outperform
Price Target: $24 → $25
Current: $19.83
Upside: +26.07%
Mar 19, 2024
Maintains: Outperform
Price Target: $11 → $9
Current: $2.91
Upside: +209.28%
Oct 3, 2023
Maintains: Outperform
Price Target: $32 → $28
Current: $13.08
Upside: +114.07%
Jun 1, 2023
Initiates: Outperform
Price Target: $16
Current: $4.40
Upside: +263.64%
May 23, 2023
Initiates: Outperform
Price Target: $7
Current: $2.99
Upside: +134.11%
May 2, 2023
Maintains: Outperform
Price Target: $4 → $1.25
Current: $1.59
Upside: -21.38%
Apr 13, 2023
Initiates: Outperform
Price Target: $44
Current: $13.21
Upside: +233.08%
Feb 7, 2023
Maintains: Outperform
Price Target: $60 → $58
Current: $19.45
Upside: +198.20%
Nov 18, 2022
Maintains: Outperform
Price Target: $18 → $24
Current: $25.61
Upside: -6.29%
Nov 10, 2022
Downgrades: Underperform
Price Target: $18
Current: $15.48
Upside: +16.28%
Aug 29, 2022
Maintains: Outperform
Price Target: $9 → $6
Current: $4.26
Upside: +40.85%
Jun 1, 2022
Maintains: Outperform
Price Target: $46 → $31
Current: $6.90
Upside: +349.28%
Mar 3, 2022
Upgrades: Neutral
Price Target: $36 → $28
Current: $7.34
Upside: +281.47%
Feb 12, 2021
Downgrades: Neutral
Price Target: $170 → $175
Current: $245.44
Upside: -28.70%
Jan 14, 2021
Downgrades: Neutral
Price Target: $14
Current: $4.78
Upside: +192.89%
Jan 12, 2021
Downgrades: Neutral
Price Target: $108
Current: $118.97
Upside: -9.22%
Aug 10, 2020
Maintains: Buy
Price Target: $80 → $78
Current: $35.63
Upside: +118.92%
Apr 6, 2020
Maintains: Buy
Price Target: $140 → $100
Current: $3.19
Upside: +3,034.80%
Apr 1, 2020
Maintains: Buy
Price Target: $24 → $6
Current: $0.46
Upside: +1,204.35%
Mar 26, 2020
Maintains: Buy
Price Target: $16 → $15
Current: $0.61
Upside: +2,353.79%
Mar 17, 2020
Upgrades: Buy
Price Target: n/a
Current: $2.19
Upside: -
Sep 24, 2019
Maintains: Buy
Price Target: $19 → $15
Current: $8.70
Upside: +72.41%
Aug 17, 2018
Maintains: Neutral
Price Target: $240 → $120
Current: $1.03
Upside: +11,550.49%
Nov 10, 2017
Maintains: Buy
Price Target: $15 → $19
Current: $9.01
Upside: +110.88%